Table 3.

Sensitivity analyses estimating overall hazard ratios for ever versus never users of rosiglitazone for prostate cancer.

Model	Hazard ratio	95% Confidence interval	P value
I. Excluding patients who had been screened by prostate-specific antigen before prostate cancer diagnosis	0.838	(0.518-1.355)	0.4706
II. Excluding patients with a diagnosis of other cancers during follow-up	1.085	(0.806-1.462)	0.5896
III. Excluding patients with a diagnosis of benign prostatic hyperplasia	0.854	(0.329-2.214)	0.7454
IV. Excluding patients with a diagnosis of nephropathy	1.133	(0.784-1.638)	0.5058
V. Excluding patients with a diagnosis of urinary tract disease	1.295	(0.698-2.404)	0.4119
VI. Excluding patients with a diagnosis of benign prostatic hyperplasia/nephropathy/urinary tract disease	1.293	(0.289-5.776)	0.7369
VII. Excluding patients aged <45 years	1.090	(0.809-1.469)	0.5699